An OHSU News story highlights new findings re: Alzheimer’s and vascular dementia. Stephen Back, M.D., Ph.D., says, “We’ve missed a major form of cell death in Alzheimer’s disease and vascular dementia. We hadn’t been giving much attention to microglia as vulnerable cells, and white matter injury in the brain has received relatively little attention."

An OHSU News story highlights new findings re: Alzheimer’s and vascular dementia. Stephen Back, M.D., Ph.D., says, “We’ve missed a major form of cell death in Alzheimer’s disease and vascular dementia. We hadn’t been giving much attention to microglia as vulnerable cells, and white matter injury in the brain has received relatively little attention.”

An OHSU News story highlights new findings re: Alzheimer’s and vascular dementia. Stephen Back, M.D., Ph.D., says, “We’ve missed a major form of cell death in Alzheimer’s disease and vascular dementia. We hadn’t been giving much attention to microglia as vulnerable cells, and white matter injury in the brain has received relatively little attention.”

A nonhuman primate study indicates that a vaccine candidate being developed by Mark Slifka, Ph.D., prevents diarrhea caused by the Capylobacter bacteria and also promotes faster growth in infants.

On International Overdose Awareness Day, OHSU hosts an educational booth about overdose signs and how the public can help by carrying Narcan and knowing how to administer it.

A WIRED profile, adapted from a new novel on personalized medicine, details the role Gleevec played in the history of personalized medicine. The author praises the development of the drug to treat patients with a form of leukemia, calling it “the stuff of legends,” but notes the drug has “harrowing financial repercussions that persist today.” The story acknowledges Brian Druker, M.D.’s, role in developing the drug and advocating against the “unsustainable prices of cancer drugs.”

A nonhuman primate study indicates that a vaccine candidate being developed by Mark Slifka, Ph.D., prevents diarrhea caused by the Capylobacter bacteria and also promotes faster growth in infants.

Kaitlyn Gregersen, an OHSU Doernbecher cardiology patient, shares her experience at Merry Heart Children’s Camp, which provides a safe summer camp experience for youth with heart conditions.

ONA-represented employees will decide whether to authorize a strike Sept. -Sept. 17. On Tuesday, Aug. 29, the OHSU and ONA bargaining teams met for continued mediation, OHSU presented a package supposal, and the parties will next meet for mediation on Sept. 13 - 15.

The New Yorker highlights the state of gene editing, including research by Shoukhrat Mitalipov, Ph.D. Mitalipov has advanced the science involved in heritable genome editing and believes the technology will help prevent disease in people: “The diseases will keep recurring over and over. If you want to really get rid of the root, you have to go back to the germline.” The story also highlights a Portland family affected by inherited disease. Marlo Urbina says, “I think most Americans would say that we do this kind of science so that we can cure these things. And to me the best cure is keeping the disease from happening in the first place.”